Petr Kavan

FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer

Thierry Conroy, Pascal Hammel, Mohamed Hebbar et al. · New England Journal of Medicine · 2018 · 2.8K citations · Full text

Medicine, Oncology, Pharmacology +14

Bevacizumab plus Radiotherapy–Temozolomide for Newly Diagnosed Glioblastoma

Olivier Chinot, Wolfgang Wick, Warren Mason et al. · New England Journal of Medicine · 2014 · 2.5K citations · Full text

Medicine, Oncology, Pharmacotherapy +15

Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial

Michael Weller, Nicholas Butowski, David Tran et al. · The Lancet Oncology · 2017 · 1.1K citations

Medicine, Oncology, Pharmacology +13

Phase II Open-Label Study of Pembrolizumab in Treatment-Refractory, Microsatellite Instability–High/Mismatch Repair–Deficient Metastatic Colorectal Cancer: KEYNOTE-164

Dung T. Le, Tae Won Kim, Eric Van Cutsem et al. · Journal of Clinical Oncology · 2019 · 1K citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial

Shukui Qin, Minshan Chen, Ann‐Lii Cheng et al. · The Lancet · 2023 · 488 citations · Full text

Medicine, Oncology, Pharmacotherapy +14